Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study - PubMed
3 hours ago
- #Patient-reported outcomes
- #CAR T-cell therapy
- #Adverse events
- Twelve of nineteen symptomatic adverse events were reported by over 50% of patients on day 10 after CAR T-cell infusion, with fatigue being the most common at 87%.
- Moderate to severe symptoms, notably fatigue (55%) and decreased appetite (53%), were frequently reported by patients, highlighting a significant symptom burden.
- Physicians consistently under-reported adverse events compared to patients, especially gastrointestinal symptoms, with under-reporting rates as high as 78% for difficulty swallowing.
- The study involved 170 patients with aggressive B-cell lymphomas across Italy, treated with axicabtagene ciloleucel (58%), tisagenlecleucel (23%), or brexucabtagene autoleucel (19%).
- Discrepancies between patient-reported and clinician-reported symptoms suggest a need for systematic use of patient-reported outcome measures for more accurate symptom monitoring.
- Factors predicting the short-term burden of therapy included sociodemographic, clinical data, and pre-infusion patient-reported physical functioning, assessed via multivariable analysis.